Mucosis B.V.
Meditech Center
L.J. Zielstraweg 1
9713 GX Groningen
The Netherlands
Trade Register / KvK: 02096219
Mucosis’s lead program FluGEM™ is aimed at developing a new influenza vaccine that can be administered to humans by a simple spray in the nose. The program is particularly directed at achieving better protection against seasonal influenza in vulnerable people, such as children and elderly. Mucosis also runs programs aiming at the development of biodefense vaccines and vaccines to prevent pneumococcal diseases.
31.05.10 Mucosis receives financial support from the Dutch government for its FluGEM program
more >
27.04.10 Mucosis appoints Dr. Roberto Grimandi as chief medical officer
more >
22.09.09 Mucosis receives key US patent covering its Mimopath™ technology
more >
28.01.09 Mucosis B.V. and PATH start development of pneumococcal vaccines
more >
15.12.08 Mucosis B.V. and TNO announce flu vaccine research and development partnership.
more >
10.12.07 News article in “Het Financieele Dagblad”.
more >
06.11.08 Mucosis B.V. appoints Dr. Govert Schouten as CEO. more >
10.09.07 Mucosis raises € 3 million in first financing round more >